Capstone wind-down continues as company divests last two drug candidates
This article was originally published in Scrip
Executive Summary
As it wraps up work on its two drug candidates and returns the related intellectual property to the inventors, Capstone Therapeutics must wait until a whistleblower lawsuit is resolved before it distributes the last of its cash to shareholders.